Making the treatment fit seamlessly into people's actual lives
Foundayo can be taken anytime without food/water restrictions, unlike Wegovy which requires morning dosing 30 minutes before eating. Pricing starts at $149/month for lowest doses, with Medicare coverage at $50 copay from July 1st, expanding access to obesity treatment.
- Foundayo approved by FDA on Wednesday as second GLP-1 pill for weight loss
- Can be taken anytime without food or water restrictions, unlike Wegovy
- Pricing starts at $149/month for uninsured patients; Medicare covers at $50 copay from July 1st
- Clinical trials showed 12% average weight loss at highest doses over 72 weeks
- Lilly estimates fewer than 1 in 10 eligible Americans currently use GLP-1 drugs
FDA approved Foundayo, Eli Lilly's second GLP-1 pill for weight loss, offering fewer restrictions than competitor Wegovy and starting at $149/month for uninsured patients.
The Food and Drug Administration cleared a second pill-form GLP-1 medication on Wednesday, handing Eli Lilly another foothold in the rapidly expanding weight-loss drug market. The medication, orforglipron, sold under the brand name Foundayo, arrives just months after its competitor Novo Nordisk won approval for a pill version of Wegovy. Both drugs represent a significant shift in how Americans can access GLP-1 treatments, which have already transformed obesity and diabetes care across the country.
Founded on the same hormonal mechanism as its injectable cousins—Lilly's own Zepbound and Mounjaro, plus Novo Nordisk's Wegovy and Ozempic—Foundayo distinguishes itself through a practical advantage. Unlike Wegovy's pill, which must be taken in the morning on an empty stomach, at least 30 minutes before food or drink, Foundayo can be taken at any time of day without dietary restrictions. The difference may seem minor, but Lilly's chief scientific officer, Dan Skovronsky, framed it as central to the company's ambition: making the treatment fit seamlessly into people's actual lives rather than asking people to reshape their routines around the medicine.
The pricing structure signals a deliberate effort to broaden access. Foundayo will cost $149 monthly at the lowest doses for patients paying out of pocket—a dramatic reduction from what GLP-1 drugs cost before a pricing agreement struck with the Trump administration last November. At higher doses, the monthly cost climbs to $349, though Lilly is offering a $299 cap for patients who refill within 45 days. For those with commercial insurance, a coupon program could reduce the cost to $25 monthly. Most significantly, Medicare will cover the pill starting July 1st with a copay capped at $50 per month, a move that could unlock treatment for millions of older Americans currently priced out of these medications.
The clinical evidence supporting Foundayo shows meaningful but modest weight loss compared to the injectable versions. In trials, patients taking the highest dose lost an average of 12 percent of their body weight over 72 weeks, compared to less than 1 percent for those on placebo. The injectable medications have achieved losses exceeding 20 percent, while Novo Nordisk reported that Wegovy's pill version produced average losses up to 17 percent at the highest doses. Lilly also tested what happens when people switch from injectables to the pill: those moving from Wegovy regained about 2 pounds on average, while those switching from Zepbound regained roughly 11 pounds, suggesting the pill can help maintain weight loss even if it doesn't produce the same initial drop.
Skovronsky emphasized that Lilly estimates fewer than one in ten Americans who could benefit from a GLP-1 drug currently uses one of the injectable versions. The pill, the company argues, may appeal to people with less severe obesity who have hesitated to commit to weekly injections. Foundayo is approved for adults with obesity or overweight who have weight-related medical conditions such as high blood pressure. The drug carries the same common side effects as other GLP-1 medications—nausea, constipation, and gastrointestinal distress—along with occasional hair loss. It has not been tested in children, and pregnant people should not use it; women taking birth control pills should consult their doctors, as Foundayo may reduce contraceptive effectiveness.
The medication will begin shipping free to patients' homes through Lilly's direct-to-consumer platform on April 6th, with broader availability through pharmacies and telemedicine services following shortly after. Novo Nordisk, meanwhile, has responded with its own pricing adjustments, offering Wegovy's pill at subscription rates between $249 and $329 monthly for uninsured patients, though the lowest-dose option remains at $149. What emerges is a competitive landscape where price and convenience have become as central to the pitch as the drugs' actual effects—a recognition that for obesity treatment to reach the millions who need it, the barrier cannot simply be efficacy. It must also be accessibility.
Citas Notables
We've designed this to fit as easily as possible into people's lives.— Dr. Dan Skovronsky, Eli Lilly's chief scientific and product officer
We really want to democratize obesity and overweight treatment for the millions of Americans who need it.— Dr. Dan Skovronsky, Eli Lilly
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that Foundayo can be taken anytime, without food restrictions? Isn't that a small thing compared to how much weight people actually lose?
It sounds small until you live it. Wegovy requires you to wake up, wait 30 minutes before coffee or breakfast, then take the pill. For some people that's fine. For others—someone working night shifts, someone traveling, someone whose life doesn't fit a morning routine—it's a real friction point. Lilly is betting that removing that friction gets more people to actually take the drug consistently.
The weight loss numbers are lower than the injectables. Twelve percent versus twenty percent. So why would someone choose the pill if the shot works better?
Because the shot is a commitment. You're getting an injection every week. Some people have needle anxiety. Some people don't want to be that visible about their treatment. A pill is private, portable, normal-looking. And for someone with mild obesity, twelve percent loss might be enough to improve their blood pressure or blood sugar without the psychological weight of a weekly injection.
The pricing is interesting. $149 a month sounds cheap compared to what these drugs used to cost, but it's still $1,800 a year for someone paying out of pocket. That's not accessible to most people.
True. But the coupon brings it to $25 for insured people, and Medicare covers it at $50 starting in July. Lilly is essentially saying: the uninsured pay more, but we're making sure insurance companies and the government subsidize it heavily. It's a tiered system, not universal access, but it's wider than before.
Lilly says less than 10 percent of eligible Americans are using GLP-1 drugs. What's stopping the other 90 percent?
Cost is one thing, but so is awareness, willingness, and access to a doctor who prescribes them. And there's still stigma—some people see these drugs as cheating, or they're skeptical that a pill will work. The pill removes one barrier. It won't remove all of them.